Cabaletta Bio, Inc. — Q2 2023 Form 10-Q Summary
Business context and reporting period
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies for autoimmune diseases through its CABA platform, including CARTA and CAART approaches. The filing covers the quarter and six months ended June 30, 2023. The company had 77 full-time and two part-time employees as of June 30, 2023, and 39,805,032 common shares outstanding as of August 4, 2023.
- Lead CARTA candidate: CABA-201, a fully human CD19-CAR T therapy.
- CAART programs: DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK myasthenia gravis.
- The company has no approved products and has not generated product revenue.
Financial performance and liquidity
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Research and development expense | $11.8 million in 2023; $9.5 million in 2022 | $24.2 million in 2023; $18.7 million in 2022 |
| General and administrative expense | $4.1 million in 2023; $3.5 million in 2022 | $8.6 million in 2023; $7.4 million in 2022 |
| Total operating expenses | $15.9 million in 2023; $13.1 million in 2022 | $32.8 million in 2023; $26.1 million in 2022 |
| Net loss | $14.5 million in 2023; $12.9 million in 2022 | $30.3 million in 2023; $25.9 million in 2022 |
| Net loss per share | $0.37 basic and diluted loss | $0.81 basic and diluted loss |
| Interest income | $1.4 million in 2023; $0.2 million in 2022 | $2.5 million in 2023; $0.2 million in 2022 |
Margins and revenue-based profitability measures are not meaningful because the company has no product revenue. Accumulated deficit was $195.9 million at June 30, 2023.
- Cash and cash equivalents: $128.1 million.
- Short-term investments: $48.3 million.
- Total cash, cash equivalents and short-term investments: $176.3 million, compared with $106.5 million at December 31, 2022.
- Net cash used in operating activities: $24.5 million for the six months ended June 30, 2023, compared with $24.3 million in the prior-year period.
- Net cash used in investing activities: $23.5 million, primarily reflecting purchases of short-term investments.
- Net cash provided by financing activities: $94.5 million, primarily from the May 2023 equity offering.
- Total liabilities were $10.5 million, consisting primarily of accounts payable, accrued liabilities and operating lease liabilities. The filing does not report outstanding debt or a credit facility.
Material changes versus the prior comparable period
- Research and development expense increased $5.5 million, driven by higher personnel costs, development services, intellectual-property licensing costs and support for CABA-201 activities, partially offset by the completion of certain sponsored research activities in 2022.
- General and administrative expense increased $1.2 million, primarily from higher personnel and stock-based compensation costs and increased public-company administrative expenses.
- Net loss increased $4.5 million for the first six months despite a $2.3 million increase in interest income.
- In May 2023, the company issued 8,337,500 common shares at $12.00 per share and received net proceeds of $93.8 million.
- The prior 2020 at-the-market sales agreement with Cowen was terminated effective May 10, 2023. A new $100.0 million ATM program was established under a 2023 shelf registration statement; no shares had been sold under the new program as of the filing.
- The company expanded its Oxford Biomedica license and supply agreement to include CABA-201 for a $0.5 million upfront fee.
- Stock-based compensation increased to $5.3 million for the first six months of 2023 from $3.6 million in the prior-year period.
Guidance, outlook, commentary and risks
Management stated that existing cash, cash equivalents and short-term investments are expected to fund projected operations into the fourth quarter of 2025 based on the current operating plan. The filing also states that additional financing will be required to complete clinical development and fund operations beyond that period. There is no committed credit facility or other committed source of capital.
- The FDA cleared CABA-201 IND applications for SLE in March 2023 and myositis in May 2023. CABA-201 also received fast track designation for SLE and lupus nephritis.
- The planned CABA-201 Phase 1/2 studies include small parallel cohorts in SLE, lupus nephritis and three myositis subtypes. These studies represent initial human evaluation of CABA-201.
- The DesCAARTes trial of DSG3-CAART continued enrolling. The company reported modestly increased persistence in an IVIg and cyclophosphamide combination cohort and began enrolling a cohort incorporating IVIg, fludarabine and cyclophosphamide.
- Management is evaluating timelines for the MusCAARTes trial based on emerging DesCAARTes data.
- Key risks include clinical failure or safety events, cytokine release syndrome, neurotoxicity, infections, B-cell aplasia or hypogammaglobulinemia, patient enrollment delays, manufacturing complexity, limited manufacturing capacity, dependence on Penn and WuXi, intellectual-property license termination, regulatory uncertainty and the need for additional capital.
- The company relies significantly on Penn for research, development and manufacturing services and on WuXi for MuSK-CAART manufacturing. Penn has indicated it cannot provide clinical supply for potential late-phase trials, requiring future technology transfer to other manufacturers.
- The company reported no material litigation as of June 30, 2023, and stated that disclosure controls and procedures were effective at a reasonable assurance level.
Most important facts for investors to verify
- Whether the stated cash runway through the fourth quarter of 2025 remains valid as clinical spending and enrollment progress.
- Enrollment, safety, persistence, pharmacodynamic and efficacy data from DesCAARTes, MusCAARTes and the initial CABA-201 trials.
- The timing and cost of transferring manufacturing from Penn and securing scalable late-stage and commercial manufacturing capacity.
- Future equity issuance under the $100.0 million ATM program or other financings, including potential dilution.
- Milestone, royalty and sublicense obligations under the Penn, IASO, Oxford Biomedica, Autolus and other agreements.
- Whether clinical-trial safety events, regulatory requirements or enrollment delays alter development timelines or cash consumption.